▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany
As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.
View More ⏩Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, GermanyNew insights into liver macrophages in NASH pathogenesis
Prof Tacke, Germany reviews the epidemiological challenge of NAFLD and NASH worldwide, especially with the obesity pandemic. He describes the clinical impact of inflammation and fibrosis in NAFLD and the role of macrophages. Finally, he discusses the possible therapeutic implications.
View More ⏩New insights into liver macrophages in NASH pathogenesisNon-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1
Prof. Chris Byrne (UK) discusses NAFLD as a multisystem disease and how NAFLD is a risk factor for other extra hepatic diseases beyond the liver
View More ⏩Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2
It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.
View More ⏩Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2DPhase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Prof. Arun Sanyal (USA) talks about and explores phase 3 development in NASH as part of the PanNash initiative as well as drug development and so on
View More ⏩Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)NASH treatment: State of the art in 2020
NASH treatment: State of the art in 2020
Management of patients with T2D and NAFLD: the role of PPAR-γ
Exploring the role of PPAR-y in the management of patients with Type 2 Diabetes and NAFLD with Prof. Kenneth Cusi (USA)
View More ⏩Management of patients with T2D and NAFLD: the role of PPAR-γNonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.
View More ⏩Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.
View More ⏩Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)PPAR gamma agonist
Prof. Frank M. Sacks discussing the role that Pioglitazone plays as a relevant #PPAR agonist
View More ⏩PPAR gamma agonistBiomarkers in NASH
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩Biomarkers in NASH